Answers are grounded in this paper and cite their sources.
Measuring plasma chymotrypsin-like activity may provide a powerful biomarker for risk stratification in patients with AML and advanced-stage MDS, including those with normal karyotype.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: